Context Therapeutics (NASDAQ:CNTX) Research Coverage Started at D. Boral Capital

D. Boral Capital initiated coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a report released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $9.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Context Therapeutics in a research note on Monday, September 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $6.80.

Context Therapeutics Trading Up 2.0 %

NASDAQ:CNTX opened at $1.50 on Monday. Context Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.75. The company has a market cap of $112.50 million, a PE ratio of -1.65 and a beta of 2.25. The company’s 50 day moving average is $1.96 and its two-hundred day moving average is $2.07.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, analysts expect that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CNTX. Great Point Partners LLC purchased a new position in Context Therapeutics during the second quarter valued at approximately $14,876,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth approximately $10,348,000. Driehaus Capital Management LLC acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth approximately $4,527,000. Nantahala Capital Management LLC purchased a new position in shares of Context Therapeutics during the 2nd quarter valued at approximately $3,881,000. Finally, Franklin Resources Inc. acquired a new position in shares of Context Therapeutics in the 3rd quarter valued at $3,689,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.